

**P059**

**cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation**

A Cantalupo<sup>1</sup>, E Mitidieri<sup>1</sup>, V Vellecco<sup>1</sup>, MR Bucci<sup>1</sup>, A Papapetropoulos<sup>2</sup>, R Wang<sup>3</sup>, R Feil<sup>4</sup>, G Cirino<sup>1</sup>.  
<sup>1</sup>University of Naples Federico II, Experimental Pharmacology 80131, Italy, <sup>2</sup>University of Patras, Department of Pharmacy, Greece, <sup>3</sup>Lakehead University, Department of Biology, Canada, <sup>4</sup>Universität Tübingen, Interfakultäres Institut für Biochemie, Germany

**Background and aim.** A growing body of evidence suggests that hydrogen sulfide (H<sub>2</sub>S) is a signaling molecule in mammalian cells. In the cardiovascular system, H<sub>2</sub>S enhances vasodilatation and angiogenesis (Szabo and Papapetropoulos, 2011). H<sub>2</sub>S-induced vasodilatation is hypothesized to occur through ATP-sensitive potassium channels; however, recently it has been demonstrated that H<sub>2</sub>S also increases cGMP levels in tissues (Bucci et al., 2010). Herein, we studied the involvement of cGMP-dependent protein kinase-I in H<sub>2</sub>S-induced vasorelaxation.

**Methods and results.** Pretreatment of aortic rings with sildenafil attenuated NaHS-induced relaxation (E<sub>max</sub> 75.2 ± 12.2% vs. 91.3 ± 7.2%, sildenafil and vehicle respectively; n=4), confirming previous findings that H<sub>2</sub>S is a phosphodiesterase inhibitor. In line with the notion that H<sub>2</sub>S is an inhibitor of phosphodiesterase, vascular tissue levels of cGMP in cystathionine gamma lyase (CSE) knockouts were lower than those in wild-type control mice (aorta 9.55 ± 0.80 pmole/mg vs. 23.40 ± 1.44 pmole/mg protein, CSE<sup>-/-</sup> mice vs. wild-type mice respectively; n=5; mesenteric artery 0.42 ± 0.04 pmole/mg protein vs. 1.57 ± 0.05 pmole/mg protein, CSE<sup>-/-</sup> mice vs. wild-type mice respectively; n=5). Treatment of aortic rings with NaHS, a fast releasing H<sub>2</sub>S donor, enhanced phosphorylation of vasodilator-stimulated phosphoprotein in a time-dependent manner, suggesting that cGMP-dependent protein kinase (PKG) is activated after exposure to H<sub>2</sub>S. Incubation of rings with a PKG-I inhibitor (DT-2) attenuated NaHS-stimulated relaxation (E<sub>c50</sub> 1.9x10<sup>-4</sup>M vs. 7.1x10<sup>-5</sup>M DT-2 vs vehicle respectively; n=6). Interestingly, vasodilatory responses to a slowly releasing H<sub>2</sub>S donor (GYY 4137) were unaffected by DT-2 (46.6 ± 8.8 vs. 32.2 ± 9.4 vehicle and DT-2 respectively, n=7), suggesting that this donor dilates mouse aorta through PKG-independent pathways. In agreement to what was observed with DT-2, dilatory responses to NaHS and L-cysteine (a substrate for H<sub>2</sub>S production) were reduced in vessels of PKG-I knockout mice (NaHS, 92.0 ± 3.0 vs. 68.3 ± 3.6 WT and PKG-KO respectively, n=7; L-cys, 23.1 ± 2.1 vs. 10.0 ± 2.8 WT and PKG-KO respectively, n=12).

**Conclusion.** Our results confirm the role of cGMP in the vascular responses to H<sub>2</sub>S and demonstrate that PKG-I regulates H<sub>2</sub>S-stimulated vasodilation.